Mild cognitive impairment

CONTINUUM Lifelong Learning in Neurology

Volumn 22, Issue 2, Dementia, 2016, Pages 404-418

  Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; CLINICAL EVALUATION; COGNITION; DEMENTIA; DISEASE COURSE; HUMAN; MEMORY DISORDER; MENTAL HEALTH; MILD COGNITIVE IMPAIRMENT; MOOD; NOMENCLATURE; PREVALENCE; REVIEW; COGNITIVE DYSFUNCTION; PATHOPHYSIOLOGY;

COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; HUMANS;

EID: 84963613163     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000313     Document Type: Review

References (52)

1. Jack CR Jr, Albert MS, Knopman DS, Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association 2011; 7 (3): 257-262. doi:10.1016/j.jalz.2011.03.004.
2. Petersen RC,. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256 (3): 183-194. doi:10.1111/j.1365-2796.2004.01388.x.
3. Petersen RC,. Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364 (23): 2227-2234. doi:10.1056/NEJMcp0910237.
4. Petersen RC, Caracciolo B, Brayne C, Mild cognitive impairment: a concept in evolution. J Intern Med 2014; 275 (3): 214-228. doi:10.1111/joim.12190.
5. Reisberg B, Ferris S, de Leon MJ,. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-Associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev Res 1988; 15 (2-3): 101-114. doi:10.1002/ddr.430150203.
6. Petersen RC, Smith GE, Waring SC, Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56 (3): 303-308. doi:10.1001/archneur.56.3.303.
7. Winblad B, Palmer K, Kivipelto M, Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256 (3): 240-246. doi:10.1111/j.1365-2796.2004.01380.x.
8. Petersen RC, Mild Cognitive Impairment. Continuum (Minneap Minn). 2004; 10 (1 Dementia): 9-28. doi:10.1212/01.CON.0000293545.39683.cc.
9. Albert MS, DeKosky ST, Dickson D, The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 270-279. doi:10.1016/j.jalz.2011.03.008.
10. Doody RS, Ferris SH, Salloway S, Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72 (18): 1555-1561. doi:10.1212/01.wnl.0000344650.95823.03.
11. Feldman HH, Ferris S, Winblad B, Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6 (6): 501-512. doi:10.1016/S1474-4422(07)70109-6.
12. Thal LJ, Ferris SH, Kirby L, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; 30 (6): 1204-1215. doi:10.1038/sj.npp.1300690.
13. Winblad B, Gauthier S, Scinto L, Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008; 70 (22): 2024-2035. doi:10.1212/01.wnl.0000303815.69777.26.
14. Petersen RC, Thomas RG, Grundman M, Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352 (23): 2379-2388. doi:10.1056/NEJMoa050151.
15. McKhann GM, Knopman DS, Chertkow H, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 263-269. doi:10.1016/j.jalz.2011.03.005.
16. Sperling RA, Aisen PS, Beckett LA, Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Assocation workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3): 280-292. doi:10.1016/j.jalz.2011.03.003.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. Washington, DC: American Psychiatric Publishing, 2013.
18. Dubois B, Feldman HH, Jacova C, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6 (8): 734-746. doi:10.1016/S1474-4422(07)70178-3.
19. Dubois B, Feldman HH, Jacova C, Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9 (11): 1118-1127. doi:10.1016/S1474-4422(10)70223-4.
20. Dubois B, Feldman HH, Jacova C, Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13 (6): 614-629. doi:10.1016/S1474-4422(14)70090-0.
21. Busse A, Hensel A, Gühne U, Mild cognitive impairment: long-Term course of four clinical subtypes. Neurology 2006; 67 (12): 2176-2185. doi:10.1212/01.wnl.0000249117.23318.e1.
22. Di Carlo A, Lamassa M, Baldereschi M, CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 2007; 68 (22): 1909-1916. doi:10.1212/01.wnl.0000263132.99055.0d.
23. Ganguli M, Chang CC, Snitz BE, Prevalence of mild cognitive impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. Am J Geriatr Psychiatry 2010; 18 (8): 674-683. doi:10.1097/JGP.ob013e3181cdee4f.
24. Larrieu S, Letenneur L, Orgogozo JM, Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59 (10): 1594-1599. doi:10.1212/01.WNL.0000034176.07159.F8.
25. Lopez OL, Jagust WJ, DeKosky ST, Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol 2003; 60 (10): 1385-1389. doi:10.1001/archneur.60.10.1385.
26. Manly JJ, Tang MX, Schupf N, Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63 (4): 494-506. doi:10.1002/ana.21326.
27. Petersen RC, Roberts RO, Knopman DS, Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology 2010; 75 (10): 889-897. doi:10.1212/WNL.0b013e3181f11d85.
28. Roberts RO, Geda YE, Knopman DS, The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology 2012; 78 (5): 342-351. doi:10.1212/WNL.0b013e3182452862.
29. Unverzagt FW, Gao S, Baiyewu O, Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology 2001; 57 (9): 1655-1662. doi:10.1212/WNL.57.9.1655.
30. Okello A, Koivunen J, Edison P, Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET Study. Neurology 2009; 73 (10): 754-760. doi:10.1212/WNL.ob013e3181b23564.
31. Lopez OL, Becker JT, Chang YF, Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study-Cognition Study. Neurology 2012; 79 (15): 1599-1606. doi:10.1212/WNL.0b013e31826e25f0.
32. Nasreddine ZS, Phillips NA, Bédirian V, The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53 (4): 695-699. doi:10.1111/j.1532-5415.2005.53221.x.
33. Kokmen E, Naessens JM, Offord KP,. A short test of mental status: description and preliminary results. Mayo Clin Proc 1987; 62 (4): 281-288. doi:10.1016/S0025-6196(12)61905-3.
34. Weiner MW, Veitch DP, Aisen PS, Alzheimer's Disease Neuroimaging Initiative. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement 2015; 11 (7): 865-884. doi:10.1016/j.jalz.2015.04.005.
35. Dickerson BC, Salat DH, Greve DN, Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005; 65 (3): 404-411. doi:10.1212/01.wnl.0000171450.97464.49.
36. Landau SM, Harvey D, Madison CM, Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75 (3): 230-238. doi:10.1212/WNL.0b013e3181e8e8b8.
37. Landau SM, Mintun MA, Joshi AD, Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72 (4): 578-586. doi:10.1002/ana.23650.
38. Prestia A, Caroli A, van der Flier WM, Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013; 80 (11): 1048-1056. doi:10.1212/WNL.0b013e3182872830.
39. Petersen RC, Aisen P, Boeve BF, Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013; 74 (2): 199-208. doi:10.1002/ana.23931.
40. Petersen RC, Smith GE, Ivnik RJ, Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273 (16): 1274-1278. doi:10.1001/jama.1995.03520400044042.
41. Johnson KA, Schultz A, Betensky RA, Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016; 79 (1): 110-119. doi:10.1002/ana.24546.
42. Mattsson N, Insel PS, Donohue M, Alzheimer's Disease Neuroimaging Initiative. Predicting reduction of cerebrospinal fluid β-Amyloid 42 in cognitively healthy controls. JAMA Neurol 2015; 72 (5): 554-560. doi:10.1001/jamaneurol.2014.4530.
43. Mattsson N, Zetterberg H, Hansson O, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302 (4): 385-393. doi:10.1001/jama.2009.1064.
44. Hansson O, Zetterberg H, Buchhave P, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5 (3): 228-234. doi:10.1016/S1474-4422(06)70355-6.
45. Rowe CC, Ng S, Ackermann U, Imaging beta-Amyloid burden in aging and dementia. Neurology 2007; 68 (20): 1718-1725. doi:10.1212/01.wnl.0000261919.22630.ea.
46. Perry D, Sperling R, Katz R, Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev Neurother 2015; 15 (3): 327-333. doi:10.1586/14737175.2015.996551.
47. Romero K, Ito K, Rogers JA, Alzheimer's Disease Neuroimaging Initiative; Coalition Against Major Diseases. The future is now: model-based clinical trial design for Alzheimer's disease. Clin Pharmacol Ther 2015; 97 (3): 210-214. doi:10.1002/cpt.16.
48. Lautenschlager NT, Cox KL, Flicker L, Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008; 300 (9): 1027-1037. doi:10.1001/jama.300.9.1027.
49. National Institute of Health Office of the Director. NIH state-of-The-science conference statement on preventing Alzhimer's disease and cognitive decline. Volume 27, number 4. Updated April 26-28, 2010. Accessed February 9, 2016. consensus.nih.gov/2010/docs/alz/alz-stmt.pdf
50. Petersen RC, Stevens JC, Ganguli M, Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56 (9): 1133-1142. doi:10.1212/WNL.56.9.1133.
51. Roberts JS, Karlawish JH, Uhlmann WR, Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology 2010; 75 (5): 425-431. doi:10.1212/WNL.0b013e3181eb5872.
52. Institute of Medicine. Cognitive aging: progress in understanding and opportunities for action. Washington, DC: The National Academies Press, 2015.